SCHEMBL3421087

SCHEMBL3421087

CCC=Cc1ccccc1[O]

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.33
KMT2A Q03164 3/20 0.33
MAPT P10636 3/20 0.33
MEN1 O00255 2/20 0.33
ATM Q13315 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
THRB P10828 1/20 0.33
BLM P54132 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
CYSLTR2 Q9NS75 2/20 0.32
CYSLTR1 Q9Y271 2/20 0.32
EPHX2 P34913 1/20 0.31
NFE2L2 Q16236 1/20 0.31
RELA Q04206 1/20 0.31
SMPD2 O60906 1/20 0.30
TLR8 Q9NR97 1/20 0.30
MAOA P21397 1/20 0.30
MAOB P27338 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3421085 1.00 LMNA (0.33) LMNAKMT2AMAPTMEN1ATM
SCHEMBL3417562 0.83 TLR8 (0.45) LMNAKMT2AMAPTMEN1ATM
SCHEMBL3417560 0.83 TLR8 (0.45) LMNAKMT2AMAPTMEN1ATM
SCHEMBL3418372 0.80 CYSLTR2 (0.46) MAPTSMN1; SMN2ALDH1A1TSHRCYSLTR2
SCHEMBL3418375 0.80 CYSLTR2 (0.46) MAPTSMN1; SMN2ALDH1A1TSHRCYSLTR2
SCHEMBL28412294 0.78 PTGER3 (0.39) LMNAKMT2AMAPTMEN1THRB
SCHEMBL18892214 0.78 LMNA (0.56) LMNAKMT2AMEN1SMN1; SMN2THRB
SCHEMBL11835698 0.77 CYSLTR2 (0.53) CYSLTR2CYSLTR1EPHX2
SCHEMBL11835702 0.77 CYSLTR2 (0.53) CYSLTR2CYSLTR1EPHX2
SCHEMBL4319685 0.77 CYSLTR2 (0.53) CYSLTR2CYSLTR1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767739-B2 Cyanato group-containing cyclic phosphazene compound and method for producing the same FUSHIMI PHARMACEUTICAL CO., LTD. (JP) 2010-08-03 US disclosed
US-20090170983-A1 Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same FUSHIMI PHARMACEUTICAL CO., LTD. (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170983-A1 Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same CENPE, CPNE4, MCM3 LMNA 3559/4885KMT2A 539/4885MAPT 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.